Rendering

Component: (Network and Table)
Network
107 - Statement - Consolidated Statements of Cash Flows
(http://www.abiomed.com/taxonomy/role/StatementOfCashFlowsIndirect)
TableStatement [Table]
Slicers (applies to each fact value in each table cell)
Statement [Line Items]Period [Axis]
2011-04-01 - 2012-03-31
2010-04-01 - 2011-03-31
2009-04-01 - 2010-03-31
Operating activities:
 
 
 
Net income (loss)
1,495,000  
(11,755,000) 
(19,024,000) 
Adjustments required to reconcile net income (loss) to net cash provided by (used for) operating activities:
 
 
 
Depreciation and amortization
4,336,000  
3,948,000  
4,898,000  
Bad debt expense
117,000  
139,000  
22,000  
Stock-based compensation
7,773,000  
5,421,000  
5,365,000  
Write-down of inventory
1,833,000  
2,781,000  
3,536,000  
Loss on disposal of fixed assets
53,000  
29,000  
54,000  
Deferred tax provision
789,000  
970,000  
954,000  
Change in unrealized loss on marketable securities
 
 
(342,000) 
Gain on sale of WorldHeart common stock
 
(456,000) 
(6,389,000) 
Gain on settlement of investment
(1,017,000) 
 
 
Changes in assets and liabilities:
 
 
 
Accounts receivable
(5,284,000) 
(1,923,000) 
2,210,000  
Inventories
(6,229,000) 
(1,508,000) 
927,000  
Prepaid expenses and other assets
(239,000) 
161,000  
(560,000) 
Accounts payable
287,000  
2,480,000  
(1,387,000) 
Accrued expenses and other long-term liabilities
(1,330,000) 
605,000  
2,299,000  
Deferred revenue
1,050,000  
682,000  
75,000  
Net cash provided by (used for) operating activities
3,634,000  
 
1,574,000  
 
(7,362,000) 
 
Investing activities:
 
 
 
Purchases of short-term marketable securities
(24,502,000) 
(8,004,000) 
(11,869,000) 
Proceeds from the sale and maturity of short-term marketable securities
7,750,000  
7,000,000  
17,848,000  
Proceeds from the sale of WorldHeart common stock
 
456,000  
6,389,000  
Proceeds from settlement of investment
1,017,000  
 
 
Contingent milestone payment on acquisition
 
 
(1,750,000) 
Expenditures for property and equipment
(1,745,000) 
(1,804,000) 
(1,800,000) 
Net cash (used for) provided by investing activities
(17,480,000) 
 
(2,352,000) 
 
8,818,000  
 
Financing activities:
 
 
 
Proceeds from the exercise of stock options
14,257,000  
1,061,000  
639,000  
Proceeds from the issuance of stock under employee stock purchase plan
423,000  
313,000  
340,000  
Net cash provided by financing activities
14,680,000  
 
1,374,000  
 
979,000  
 
Effect of exchange rate changes on cash
(675,000) 
447,000  
568,000  
Net increase in cash and cash equivalents
159,000  
 
1,043,000  
 
3,003,000  
 
Cash and cash equivalents at beginning of year
5,831,000  
4,788,000  
1,785,000  
Cash and cash equivalents at end of year
5,990,000  
 
5,831,000  
 
4,788,000  
 
Supplemental disclosures:
 
 
 
Fixed asset additions included in accounts payable
535,000  
48,000  
107,000  
Common shares issued for business acquisition
 
 
3,827,000  
Taxes paid, net of refunds
 
 
300,000